Cargando…
Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer
Biosimilars are biological medicines that have been shown to be similar to a reference biological medicine that has already been approved for use. Development of biosimilars is based on a “totality of evidence” approach that involves a series of steps by which biosimilars must demonstrate similarity...
Autores principales: | Krendyukov, A., Schiestl, M., Höbel, N., Aapro, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694091/ https://www.ncbi.nlm.nih.gov/pubmed/28929372 http://dx.doi.org/10.1007/s00520-017-3861-y |
Ejemplares similares
-
Development and 10-year history of a biosimilar: the example of Binocrit(®)
por: Aapro, Matti, et al.
Publicado: (2018) -
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018) -
Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study
por: Aapro, Matti, et al.
Publicado: (2019) -
Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018) -
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017)